BiotechTube

Ponezumab

Phase 2Completed
0 watching 0 views this week⚡ Active
51
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cerebral Amyloid Angiopathy

Conditions

Cerebral Amyloid Angiopathy

Trial Timeline

Jun 1, 2013 → Sep 1, 2015

NCT ID
NCT01821118

About Ponezumab

Ponezumab is a phase 2 stage product being developed by Pfizer for Cerebral Amyloid Angiopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT01821118. Target conditions include Cerebral Amyloid Angiopathy.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01821118Phase 2Completed

Competing Products

20 competing products in Cerebral Amyloid Angiopathy

See all competitors
ProductCompanyStageHype Score
mouse nerve growth factorSun PharmaceuticalApproved
85
Edaravone Dexborneol + PlaceboSun PharmaceuticalPhase 2
52
Oral Glycopyrrolate LiquidShionogiPhase 3
77
recombinant human erythropoietin alfa + 0.9% NaClJohnson & JohnsonPhase 2/3
65
UDI-001Rohto PharmaceuticalPhase 1/2
41
NXY-059AstraZenecaPhase 3
77
NXY-059AstraZenecaPhase 2
52
RosuvastatinAstraZenecaApproved
85
NXY-059AstraZenecaPhase 3
77
Comparator: Placebo + Comparator: MK0724MerckPhase 2
52
Vorapaxar 2.5 mg + Vorapaxar 1 mg + Placebo + Aspirin 75-150 mgMerckPhase 2
52
Recombinant Factor VIIa + Biological/Vaccine: PlaceboNovo NordiskPhase 3
76
Recombinant Activated Factor VII (rFVIIa) + PlaceboNovo NordiskPhase 3
76
PF-05230907PfizerPhase 1
32
Azithromycin + Pyrimethamine + Leucovorin calciumPfizerPhase 1
32
clopidogrel (SR25990C)SanofiApproved
84
Intrarectal quinineSanofiPhase 3
76
PiracetamUCBApproved
82
Placebo + ALN-APPAlnylam PharmaceuticalsPhase 2
49
CN-105Tiantan BioPhase 2
49

Other Products from Pfizer

MeropenemApproved
84
celecoxibApproved
84
13vPnCApproved
84
EtanerceptApproved
84
AtorvastatinApproved
84